Inventiva To Present Data From The Final Analysis Of The Phase 2 Study Evaluating The Combination Of Lanifibranor With Empagliflozin In Patients With Mash And T2D At The AASLD The Liver Meeting Late-Breaker Session; 50% Percent Of Patients Saw Their...
Inventiva To Present Data From The Final Analysis Of The Phase 2 Study Evaluating The Combination Of Lanifibranor With Empagliflozin In Patients With Mash And T2D At The AASLD The Liver Meeting Late-Breaker Session; 50% Percent Of Patients Saw Their...
Inventiva To Present Data From The Final Analysis Of The Phase 2 Study Evaluating The Combination Of Lanifibranor With Empagliflozin In Patients With Mash And T2D At The AASLD The Liver Meeting Late-Breaker Session; 50% Percent Of Patients Saw Their HbA1c Levels Below 6.5% At Week 24 Following Treatment With Lanifibranor Alone Or In Combination With Empagliflozin
Inventiva将在AASLD The Liver会议后期讨论会上提供评估马什和T2D患者中Lanifibranor与Empagliflozin联合使用的2期研究的最终分析的数据；50％的患者在单独使用Lanifibranor或与Empagliflozin联合治疗后，在第24周看到HbA1c水平低于6.5％
- Data will be presented on Monday, November 18th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 in San Diego.
- LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo.
- 50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with empagliflozin.
- 58% of patients on lanifibranor alone and 80% of those on the combination therapy had a decrease of at least 1% in HbA1c at week 24, compared to 0% in the placebo group.
- Liver function tests, markers of liver fibrosis and markers or cardiometabolic health including HOMA-IR, hsCRP, ferritin, lipid profile and adiponectin levels were also improved with lanifibranor alone or in combination with empagliflozin.
- The weight gain observed in a proportion of patients under lanifibranor was not observed in patients treated with the combination of lanifibranor with empagliflozin.
- 数据将于11月18日星期一作为晚间海报在圣地亚哥举行的美国肝病研究协会（AASLD）2024年肝脏会议上公布。
- 与安慰剂相比，LEGEND通过显著降低拉尼菲布拉诺组和使用empagliflozin组的lanifibranor组的HbA1c水平来实现其主要疗效终点。
- 50％的患者在单独使用lanifibranor或与empagliflozin联合治疗后的第24周发现其HbA1c水平低于6.5％。
- 在单独使用拉尼布拉诺的患者中，有58％的患者和80％的联合疗法患者在第24周的HbA1c下降了至少1％，而安慰剂组的这一比例为0％。
- 单独使用lanifibranor或与empagliflozin联合使用也改善了肝功能测试、肝纤维化标志物和心脏代谢健康标志物，包括HOMA-IR、hsCRP、铁蛋白、脂质分布和脂联素水平。
- 在使用拉尼菲布拉诺与empagliflozin联合治疗的患者中，未观察到一定比例的lanifibranor患者体重增加。
Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), also known as non-alcoholic steatohepatitis ("NASH"), and other diseases with significant unmet medical needs, today announced the presentation of the final analysis of LEGEND, Phase 2 proof-of-concept clinical trial, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type 2 Diabetes (T2D). The data will be presented Monday November 18, 2024, as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting, taking place in San Diego California.
戴克斯（法国），长岛市（美国纽约），2024年11月15日——Inventiva（巴黎泛欧交易所和纳斯达克股票代码：IVA），一家临床阶段的生物制药公司，专注于开发用于治疗代谢功能障碍相关脂肪肝炎（“MASH”）（也称为非酒精性脂肪肝炎（“NASH”）和其他疾病的口服小分子疗法重大未得到满足的医疗需求，今天宣布发布LEGEND的最终分析，即2期概念验证临床试验，该试验评估了lanifibranor的联合使用empagliflozin 用于 MASH 和 2 型糖尿病 (T2D) 患者。这些数据将于2024年11月18日星期一在加利福尼亚州圣地亚哥举行的美国肝病研究协会（AASLD）肝脏会议上作为后期发布的海报公布。
